Sign up to our newsletter Subscribe
Understanding the Full Value of Long-Acting Therapies: less is more?
OHE Expert Profile
Matthew Napier
Economist
Matthew is an economist by training and after completing an MSc in Health Economics and Health Policy with a distinction from the University of Birmingham in 2022, he joined the OHE. He is supporting the prevention taskforce, defining the prevalence and burden of preventative ill health in the UK, and exploring the potential economic benefits of preventing ill health.
Matthew’s current research interests include cost effectiveness modelling, the economic evaluation rare diseases, innovative technologies, and health policies.
Latest Publications
The Importance of Diversity of Supply in Rare Diseases Markets
Read more
© VK Studio at stock.adobe.com
The Cost of Drug Shortages
Read more
© Timothy Masters at adobe.stock.com
A Framework for Value-aligned Pricing of Combination Therapies
The Socioeconomic Burden Of Cervical Cancer in the UK: What are the benefits of achieving the WHO elimination target?
